Patients with ERBB2-positive breast cancer and CNS-only metastasis are at a high risk for CNS-related death but have longer overall survival than those with concomitant extracranial metastases.

The focus of the presentation will be on the subgroup of patients who have received 100mg bezuclastinib for at least 48 weeks to highlight the symptomatic benefits of long-term use.